drugset / Trial / NCT05716295
A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is an open-label, dose escalation and dose expansion study of MDK-703 as a monotherapy and in combination with other cancer therapies in adult study participants with advanced or metastatic solid tumors.
Timeline
- Start
- 2023-02-08
- Primary completion
- 2024-04-30
- Completion
- 2024-04-30
Outcome
Outcome not reported
Stopped: “Corporate decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MDK-703 | Unknown | — | — |
Indications
No indication recorded.